1. Predictive power of the post-treatment scans after the initial or first two courses of [ 177 Lu]-DOTA-TATE;Chicheportiche;EJNMMI Physics,2018
2. Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: an Updated Review;Hatano,2023
3. Lutathera®: the First FDA-And EMA- Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy;Hennrich,2019
4. The 2007 recommendations of the international commission on radiological protection;ICRP Publication 103. Ann. ICRP,2007